Brittney Schultz
Dermatology · Minneapolis, MNNPI 1710305180
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $46,490 of the $52,329 with a category attached, or 88.8%. 5 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 43.9% of the total. Among dermatology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 62 payments — averaging $844.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$23K
- Regeneron$13K
- Argenx US, Inc.$9K
- Biocryst Pharmaceuticals, Inc.$4K
- Sanofi$4K
Across 10 payments — averaging $2252.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$14K
- UCB SA$9K
What the payments were for
- Consulting fees$46,49089%
- Travel & lodging$4,7459%
- Food & beverage$1,0932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 25 | $22,988 |
| Regeneron | 18 | $13,079 |
| Argenx US, Inc. | 13 | $8,926 |
| Biocryst Pharmaceuticals, Inc. | 5 | $3,721 |
| Sanofi | 1 | $3,615 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,329 in reported general payments places this provider in the 95th percentile of 273 dermatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 133 | $529,054 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 25 | $180,017 |
| Humira(Cf) PenAdalimumab | 15 | $154,627 |
| Dupixent SyringeDupilumab | 28 | $110,510 |
| HumiraAdalimumab | 13 | $85,751 |
| Tacrolimus | 30 | $4,510 |
| Ketoconazole | 195 | $4,459 |
| Doxycycline Monohydrate | 81 | $4,421 |
| Calcipotriene | 34 | $3,959 |
| Dapsone | 23 | $2,880 |
| Fluorouracil | 36 | $2,819 |
| Clobetasol Propionate | 86 | $2,735 |
| Mycophenolate Mofetil | 28 | $2,469 |
| Triamcinolone Acetonide | 141 | $1,902 |
| Clindamycin Phosphate | 35 | $1,149 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Minneapolis
- Margareth Pierre-LouisMinneapolis$439K
- Maria HordinskyMinneapolis$85K
- David PearsonMinneapolis$46K
- Noah GoldfarbMinneapolis$30K
- Paul BigliardiMinneapolis$21K
- Brian ZelicksonMinneapolis$14K
- Sara HylwaMinneapolis$5K
- Timothy AllenMinneapolis$3K
- Kimberly BohjanenMinneapolis$2K
- Jaime DavisMinneapolis$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.